SEED Entered into Strategic Research Collaboration with Eisai and Closed First Round of Series A Financing in August 2024.
SEED Achieved 3rd Milestone with Lilly R&D Collaboration in March 2024.
SEED Discloses Novel Molecular Glue IND Candidate at “TPD Think Tank” Symposium.
SEED Therapeutics’ Mission
To break through the scientific barriers to discovering Molecular Glues for effective therapy and cures for the world’s most debilitating diseases and disorders.
Collaborating with an unparalleled team of world-leading experts in the Ubiquitin Proteasome System and the field of Targeted Protein Degradation. SEED Therapeutics is advancing its groundbreaking Molecular Glues discovery platform for the treatment of multiple indications, including cancer, neurodegradation, and infectious diseases.
DRUG DISCOVERY
SEED Therapeutics: A focus on Molecular Glues
SEED Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use Molecular Glues to attack protein targets previously believed to be ”undruggable.”
PIPELINE
THE TEAM
Click below to learn more about SEED Therapeutics’ leadership
NEWSROOM
Nature: Protein degraders push into novel target space
Nature: Protein degraders push into novel target space Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory.
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head...
SEED Therapeutics Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of...
SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology
March 6, 2024: Nature Biotechnology, a transformative journal covering the science and business of biotechnology, published a review article on the significant challenges facing molecular glue companies seeking to remove undruggable disease-causing proteins,...
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium NEW YORK, October 26, 2023 – SEED Therapeutics Inc. (“SEED”), a...
Events
“Targeted Protein Degradation Think Tank” Symposium
PARTNERS
CAREERS
Make a difference in improving human health
CONTACT US
Investor Contact: IR@seedtherapeutics.com
Media Contact: PR@seedtherapeutics.com
General Inquires: info@seedtherapeutics.com